Your new post is loading...
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Bioscience News - GEG Tech top picks
8.8K views |
+0 today
A key drug to treat Alzheimer's disease failed a late-stage clinical trial, Eli Lilly and Company said Wednesday.
The drug, solanezumab, wasn't able to slow down cognitive decline in patients with Alzheimer's compared with those who took a placebo.